Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Inclusion criteria: * Consecutive patients aged 18 years or older * first episode of symptomatic, objectively diagnosed PVT, MVT, or spVT * signed informed consent. Exclusion criteria: * known liver cirrhosis (biopsy proven or with clinical, laboratory, or imaging evidence of chronic liver disease, within a context of chronic alcoholism, viral hepatitis, autoimmunity, Wilson's disease, iron overload) * alanine aminotransferase level that is three times the upper limit of the normal range or higher * Budd-Chiari syndrome * previous or ongoing vatical bleeding * presence of portal vein cavernoma at the time of diagnosis * anticipated abdominal surgical procedure * known bleeding diathesis * platelet count \<100.000 mm3 * creatinine clearance \<30 mL/min (Cockroft-Gault formula) * life expectancy of less than 3 months * expected inability to take oral medications * concomitant treatment with azole antimycotics and human immunodeficiency virus protease inhibitors - treatment with therapeutic doses of LMWH or UFH for more than 7 days * ongoing treatment with VKA * pregnancy or lactation